RPG Life Sciences share news, announcements and annual reports
NSE: RPGLIFEBSE: 532983Pharmaceuticals & BiotechnologySmall Cap
RPG Life Sciences Limited · Face value ₹8 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2008
Last close ₹2,549.50down ₹26.20 (1.02%)BSE ₹2,548.10
Share price at the NSE close on 2 Nov 2026. Previous close ₹2,575.70.
2 Nov: open ₹2,562.80, high ₹2,571.90, low ₹2,480.00
52-week range of traded prices to 2 Nov 2026
₹1,733.00Low, 23 Mar 2026₹3,127.80High, 25 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,217 Cr923rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.55
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.14
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.94%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it, the company's own balance sheet from before it began consolidating; the two agree where both are first on record.
- 17.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 23,32627.4% delivered
RPG Life Sciences share news and announcements
681 announcements, routine notices left out, newest first. Page 12 of 14.
Jul 2014
14 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended June 30, 2014.
Jun 2014
Apr 2014
30 Apr · Dividend
Board of Directors of the Company at its meeting held on April 30, 2014,has recommended a normal dividend of Rs. 1.20 per share (15%) and a special dividend of Rs. 0.80 per share (10%) on account of extraordinary income aggregating to total dividend of Rs. 2.00 per share (25%) for the year ended March 31, 2014, subject to the approval of the members at the ensuing Annual General Meeting.30 Apr · Results
Mar 2014
Feb 2014
Jan 2014
28 Jan · Board meeting
Inter-alia, to consider and approve the unaudited financial results for the quarter ended December 31, 2013. Further, as per SEBI (Prohibition of Insider Trading Regulation), 1992 and the Code of Conduct adopted by the Company, the 'Trading Window' for trading in the Company's securities shall remain closed for the promoters, Directors and Designated Employees of the Company from January 29, 2014 till February 10, 2014 (both days inclusive) for the purpose of declaration of quarterly financial results.
Nov 2013
29 Nov · Management
Mr. Ajit Gulabchand has resigned as Director of the Company w.e.f. November 13, 2013. The Board of Directors of the Company has approved the resignation of Mr. Gulabchand by passing Resolution by Circulation on November 28, 2013.
Oct 2013
18 Oct · Results
7 Oct · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended September 30, 2013.
Aug 2013
Jul 2013
27 Jul · Disclosure of Voting Pattern - Clause 35A
16 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended June 30, 2013.
Jun 2013
24 Jun · Corporate action
Company has fixed Book Closure from July 15, 2013 to July 26, 2013 (both days inclusive) for the purpose of Annual General Meeting and Payment of equity dividend of Rs.1.20 per share (15%) for the year ended March 31, 2013, if declared at the said Annual General Meeting.
May 2013
8 May · Dividend
Board of Directors of the Company at its meeting held on May 07, 2013 has recommended an equity dividend of Rs.1.20 per share (15%) for the year ended March 31, 2013, subject to the approval of the members at the ensuing Annual General Meeting.8 May · Board meeting
Board of Directors of the Company at its meeting held on May 07, 2013 has re-appointed Mr. Ajit Singh Chouhan as Managing Director of the Company for a further period of 3 years w.e.f. April 09, 2013, subject to the approval of the members at the ensuing Annual General Meeting.
Apr 2013
25 Apr · Board meeting
Inter alia, to consider and approve the following: (1) Audited financial results for the year ended on March 31, 2013; and (2) Recommendation of dividend for the year 2012-13, if any.10 Apr · News Verification
News Verification : The media had reports that RPG Life Sciences Limited is in pact to sell on lease right of Navi Mumbai land to Maruti Suzuki India Limited. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. RPG Life Sciences Limited has vide its letter inter-alia stated, "The news appearing in the media is premature and without confirming the facts. The company has executed an MOU with Maruti Suziki India Ltd. (MISL) for proposed sale of part of land situated at MIDC, Navi Mumbai which is subject to conclusion on fulfillment of terms and conditions mentioned therein. As a part of due diligence, MSIL through their Advocates has issued a Public Notice on April 10, 2013 in the leading news papers seeking comments and objections for proposed purchase of the said land. The Company shall make a formal announcement only on execution of a definitive sale agreement for sale of land."
Feb 2013
Jan 2013
28 Jan · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended December 31, 2012.
Oct 2012
12 Oct · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter ended September 30, 2012.
Aug 2012
24 Aug · Updates
89,000 options granted by the Company to its employees under the 2005 ESOP Scheme have been cancelled.10 Aug · Disclosure of Voting Pattern - Clause 35A